PULMONARY DRUG DELIVERY 2025
A CLOSER LOOK AT OUR GUESTS FROM ALL OVER THE WORLD
Prof. Anthony Hickey
(University of North Carolina at Chapel Hill, USA)
Dr. Hickey is Distinguished Fellow Emeritus at RTI International, and Professor Emeritus of Pharmacoengineering and Molecular Pharmaceutics of the Eshelman School of Pharmacy, and Adjunct Professor of Biomedical Engineering of the School of Medicine at the University of North Carolina at Chapel Hill.
He is founder, and former President and CEO, of Cirrus Pharmaceuticals, Inc.; founder of Oriel Therapeutics, Inc; CEO of Astartein, LLC, and Scientific Advisor to TFF Pharmaceuticals Inc.; Chair of the USP Joint Subcommittee on Nanotechnology, Member of the USP Pharmaceutical Dosage Forms Expert Committee (DFEC), and Aerosols Sub-Committee of the DFEC of the US Pharmacopeia.
He is a Fellow of the American Association for the Advancement of Science, the American Association of Pharmaceutical Scientists, The Academy of Pharmaceutical Sciences of Great Britain, the Royal Society of Biology, the Royal Society of Medicine and the National Academy of Inventors.
He received the Research Achievement Award of the Particulate Presentations and Design Division of the Powder Technology Society of Japan, the W Grant Award in Physical Pharmacy of the AAPS; Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research, the ISAM, the Ralph Shangraw Memorial Award for Excipient and Excipient Technology of the International Pharmaceutical Excipient Consortium Foundation and the KONA Award for Outstanding Contributions to Aerosol Drug Delivery Systems.
Prof. Guenther Hochhaus
University of Florida, USA
Prof. Hochhaus received his Ph.D. in 1984 at the Institute of Pharmaceutical Chemistry, Westfalia Wilhems University of Münster.
He completed a postdoctoral fellowship at the University of California-San Francisco and subsequently joined the University of Florida as an Assistant Professor in 1987, where he currently is a Professor of Pharmaceutics.
Dr. Hochhaus’ research is focused on evaluating inhalation drugs through in vitro and pharmacokinetic/dynamic approaches with special interest in identifying ways to improve lung selectivity. He collaborates with regulatory authorities to improve methodology for drug approval of generic inhalation drugs. He has published more than 240 research papers.
Dr. Hochhaus is a Fellow of AAPS and the American College of Clinical Pharmacology (ACCP). In 1998, he was recipient of the young investigator award of the German Airway and Lung Research Society and received ACCP’s Tanabe Young Investigator Award. He was awarded the University of Florida Foundation Research Professorship in 2015-2018; 2019-2022, the American College of Clinical Pharmacology’s Bristol-Myers Squibb Mentorship in Clinical Pharmacology Award (2019) and is Honorary Regent of ACCP. In 2022, he received the Charles G. Thiel Award for outstanding research and discovery in respiratory drug delivery. He was the 2024 Allen J Sedman lecturer at the University of Michigan.
Prof. Jürgen Bulitta
(University of Florida, USA)
Jürgen Bulitta, PhD, is a Professor and the Perry E. Foote Eminent Scholar Chair in the Department of Pharmacotherapy & Translational Research at the University of Florida College of Pharmacy.
Together with Dr. Guenther Hochhaus, Dr. Bulitta led five U.S. FDA grants and contracts since 2016 for research on the pharmacokinetics and bioequivalence of orally inhaled drug products (OIDPs). This includes an ongoing project that integrates physiologically based pharmacokinetic (PBPK) and population pharmacokinetic modeling of OIDPs.
Dr. Bulitta published 182 peer-reviewed papers and contributed to over 97 phase I-IV clinical studies.
Dr. Bing Li
FDA, USA
Dr. Bing V. Li is the Associate Director for Science in the Office of Bioequivalence in the Office of Generic Drugs at the U.S. Food and Drug Administration (FDA). In this role, she provides scientific leadership in the assessment of bioequivalence (BE) studies submitted through Abbreviated New Drug Applications (ANDAs), and oversees scientific initiatives, including the development and implementation of regulatory guidance.
Dr. Li is a recognized Expert Pharmacologist at the FDA, specializing in the bioequivalence of aerosolized drug products. She is the editor and author of the book FDA Bioequivalence Standards, and a recipient of the prestigious Edison Patent Award.
Dr. Li has earned her Ph.D. in Pharmaceutical Sciences from the University of Wisconsin–Madison in 2001, and her bachelor's degree in Medicinal Chemistry from Peking University, China, in 1990.
Previously, Dr. Li was a Research Investigator at Bristol-Myers Squibb, where she was responsible for formulation identification, development, and optimization of oral solid dosage forms.
Dr. Elizabeth Bielski
FDA, USA
Elizabeth Bielski, M.S., Ph.D. is a Senior Pharmacologist working at Division of Therapeutic Performance-I (DTP-I), Office of Research and Standards (ORS), Office of Generic Drugs (OGD), Center of Drug Evaluation and Research (CDER) at the FDA since January 2020.
Her area of expertise involves orally inhaled and nasal drug products (OINDPs). She is actively involved in developing general and product-specific guidances, addressing controlled correspondences, pre-ANDA meeting requests, citizen petitions, internal consults, and collaborating on current research projects to promote generic drug development of OINDPs.
Prior to joining the FDA, she served as an ORISE Fellow at FDA within DTP. Elizabeth completed her Ph.D. in Chemical Engineering in 2018, MS in Biomedical Engineering in 2012, and BS in Biomedical Physics w/ University Honors in 2011 from Wayne State University.
Dr. Gur Jai Pal Singh
BBSG Pharm Associates, USA
Dr. Gur Jai Pal Singh is the Chief Scientific Advisor at BBSG Pharm Associates since June 2023. Before that he served as a Senior VP and headed a Pharma Company’s Respiratory Centre of Excellence - providing end-to-end hand-on leadership for state-of-the-art development of inhalation drug products.
Under his leadership, several orally inhaled products have been successfully developed for the US, EU, and other geographies. Before coming to leadership roles in the private industry, Dr Singh had a 15-years tenure at the US FDA with designation of Senior Expert for Orally Inhaled and Nasal Drug Products (OINDP) - making key contributing to the Agency development of guidelines for OINDP.
He has participated by invitation in a number of expert panels debating regulatory and product development issues related to respiratory drug products, and given invited lectures at lead international forums including, but not limited to, Respiratory Drug Delivery Conferences in the US and EU, International Society for Aerosols in Medicine, Pulmonary Drug Delivery Conference, Product Quality Research Institute (FDA-Academia-Industry), and IPAC-RS conferences. Dr Singh continues to play an active role in addressing scientific and regulatory issues in the development of complex respiratory drug products, with the current embracing of inhaled biologics.
Assoc. Prof. Jenny Lam
University College London, UK
Dr. Jenny Lam is an Associate Professor of Pharmaceutics at the School of Pharmacy, University College London. Dr Lam obtained her MPharm and PhD from The University of Nottingham. In her PhD study, she investigated the use of non-viral vectors for gene delivery. Dr Lam was then awarded the Maplethorpe Fellowship, continued her research in nucleic acid delivery at King’s College London. She then joined the University of Hong Kong as Assistant Professor to help setting up a Bachelor of Pharmacy Programme and returned to the UK in 2022.
Dr Lam’s research is focused on the development of novel delivery system for a wide range of therapeutics including small molecules, nucleic acids and biologics, with special interest in the use of particle engineering methods to produce aerosol formulations for the treatment/prevention of respiratory diseases.
She is the principal investigator of a number of competitive grants. She has published over 90 peer-reviewed articles and filed a number of patent applications on pulmonary drug delivery systems. In 2020, she was awarded the DDL (Drug Delivery to the Lungs) Emerging Scientist Award which recognised her significant accomplishment and innovation in inhalation science.
prof. ayca yıldız-peköz
İstanbul University,
Pulmocures CEO, Türkiye
Dr. Ayca Yıldız-Peköz is a Professor in the Department of Pharmaceutical Technology at the Istanbul University, Turkey.
She obtained her dual Doctoral Degree in 2006 from the Istanbul University and the University of Cardiff, UK, where she has worked with Prof. Mark Gumbleton. She belongs to the first cohort of EU’s prestigious Marie Curie Scholarship in the Euro PhD program.
Dr. Yıldız-Peköz focuses on pulmonary drug targeting, regulatory aspects of inhalation drugs, bench to bedside procession of new generation inhalation drugs, including Soft Mist Inhalers, micro/nano carrier systems as localized therapies, pharmaceutical applications of cell culture studies and in situ formulations for mucosal delivery.
She holds 9 patents, six of which are COVID-19 related.
Amid the COVID-19 pandemic, Dr. Yıldız-Peköz had developed a novel patented method for the repurposing of APIs for the pulmonary targeting. She completed a Phase2 trial, whereby she proved repurposed heparin and antivirals via SMIs for high lung deposition to be effective in COVID-19 patients.
Dr. Ayca Yıldız-Peköz has 13 years of experience in the regulatory bodies and in private consulting. Dr. Yıldız-Peköz is a member of the Aerosol Society, of the local chapter of the Controlled Release Society. She is the Founding President of the Pulmonary Drug Delivery Researchers’ Association, a new and growing network of pulmonary scientists across European universities. She is the co-director of the Pulmonary Drug Delivery Workshop (PDD Istanbul) series, one of the main inhalation conferences in Europe, in collaboration with Prof. Carsten Ehrhardt of Trinity College Dublin.
Dr. Yıldız-Peköz welcomes private firms’ consulting inquiries and doctoral students in areas of pulmonary drug targeting, novel delivery technologies, formulation to scale-up consulting and regulatory advising.
Dr. Yıldız-Peköz is the Founder and Chairwoman of Pulmocures, an off-spring company of her academic research, with offices at the technopoles of Istanbul University and of Istanbul Technical University.
Prof. Carsten Ehrhardt
(Trinity College Dublin, Ireland)
Carsten is Professor in Pharmaceutics and Biopharmaceutics at the School of Pharmacy and Pharmaceutical Sciences and Fellow of Trinity College Dublin. Carsten’s research focuses on the disposition and transport of drugs following their administration to the lungs using pre-clinical in vitro and ex vivo models. Moreover, he is interested in molecular origins of airways disease.
Carsten has edited 1 book and co-authored more than 110 peer-reviewed publications. He is a board member of the International Society for Aerosols in Medicine (ISAM) and serves as Associate Editor of Journal of Aerosol Medicine and Pulmonary Drug Delivery and Section Editor of European Journal of Pharmaceutical Sciences.
Since 2013, Carsten is the mastermind of the PDD Workshops and organises the Dublin branch of the PDD Workshops, which annually alternates between Dublin and Istanbul. Carsten obtained his PhD from the Saarbrücken University of Germany. Carsten has advised several international companies, including Pulmocures of Türkiye, developing inhalation drugs for orphan diseases.
CHRIS BARON
Director Business Development Pulmonary, Aptar Pharma
Chris Baron is Director of Business Development Pulmonary Category at Aptar Pharma. In This role, he is responsible for the global business development activities for Aptar Pharma’s inhalation drug delivery solutions, as well as their respective services pertaining to the application fields of Asthma and COPD.
With an Honors degree in Mechanical Engineering, Chris has gained over 30 years of industry experience in the field of Inhalation Drug Delivery (IDD), specifically metering valve technologies for pressurized metered-dose inhalers (pMDIs) and their accessory/peripheral device technologies, including dose indicators and breath-activated inhalers.
David Farrow
Director Scientific Affairs, Aptar Pharma
Dave is Director of Scientific Affairs at Aptar Pharma, having previously served as Director of Science and Technology for Aptar Pharma's Prescription division.
Earlier in his career, Dave worked as an Inhalation Scientist at Sanofi Aventis, focusing on exploratory development and commercial products. He then expanded his inhalation expertise at Novartis. At Vectura, he progressed from Particle Engineering Specialist to Principal Scientist and Manager of the Bioformulation and Particle Engineering group. At Charles River, he led the team conducting safety assessment and toxicology studies with aerosols.
Dave also led R&D groups and business development activities at Albany Molecular Research Inc. (now Curia) before moving to Nanopharm, an Aptar Pharma company. At Nanopharm, he held the positions of Director of Operations and later, Chief Operations Officer (COO), before joining Aptar Pharma in 2024.
Nuria Manzano
Nanopharm, An Aptar Pharma Company
Nuria is a Biotechnologist and currently works as an Analytical Specialist at Nanopharm, an Aptar Pharma company, where she is an expert in alternative bioequivalence for inhaled and nasal drug products. In this role, she has led development, validation and testing tasks using a range of novel methods, and supported preANDA and post-submission meetings between FDA and Nanopharm customers.
Nuria also contributed to two FDA contracts investigating microstructural characterisation for orally inhaled and nasal drug products and has presented her work at several international conferences.
.png)
Dr. Bill Brashier
SANDOZ, UK
Bill Brashier is a Senior Clinical-Medical Scientist at Sandoz with over 22 years in respiratory research. He is an MD specializing in Pulmonology with major interest in Chronic Inflammatory disease of the lungs. He has authored several research papers in high impact peer revied Journals.
Bill's research spans from patient care to basic science, including the development of local defense cells from circulating stem cells and the role of mesenchymal stem cells in immune modulation for chronic inflammatory diseases. He has also focused on inhalation drug systems, where he bridges particulate physiology with lung physiology that has been instrumental in pioneering techniques for measuring lung function using sound waves, providing valuable insights into obstructive airway diseases.
He is invited speaker to various regulatory and clinical bodies and such as FDA and European Respiratory Society. With a European Research Fellowship from NHLI, London, Bill excels in drug development, clinical trials, and leading respiratory clinical teams.
Jaap Wieling
PureIMS
Jaap Wieling brings 30+ years of experience as an executive and entrepreneur in (bio)pharmaceutical research and development in various firms such as TNO, DSM, PRA/ICON, Xendo, QPS and BiosanaPharma. He is currently CEO of PureIMS in The Netherlands, a pharmaceutical company focused on development of dry-powder inhalation products.
He is a seasoned expert in building product and platform development businesses and serves on the board and advisory committee of various (bio)pharmaceutical companies and biopharmaceutical service industries. For many years he has been invited university lecturer on pharmaceutical product development.
He holds a BSc degree in chemistry, an MSc degree in pharmacology and a PhD degree in Mathematics and Natural Sciences from Groningen University, The Netherlands.
Prof. Paul Hagedoom
University of Groningen, The Netherlands
Paul is the Senior Technologist/Inhalation Scientist and head of the inhalation research laboratory at the Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Netherlands.
Paul has more than 30 years of experience in the field of inhalation and has (co)authored more than 100 publications in peer reviewed journals, have 4 patents and is the (co)inventor of several DPI’s like the Novolizer, Genuair, Twincer and the Cyclops. His research focuses on development of drug formulations for the pulmonary route and developing of effective dry powder inhalers.
He is the scientific advisor and chairman of the foundation Inhalation Medication Instruction School (IMIS) in the Netherlands and scientific advisor of the Lung Alliance Netherlands (LAN). He is also author of a patient care atlas and author of 5 books in the field.
Gerhard Neumaier
Miccados GmbH
Gerhard Neumaier founded Miccados GmbH in 2022. Miccados focuses on the construction and manufacture of manual and semi-automated micro-dosing devices for inhalation and nasal powders that fulfil the specific functions. The first device of Miccados was launched in 2023, and is now being used by companies in Germany, USA and China. Miccados has a solid pipeline to be launched in the near future.
Gerhard has graduated in 1981 as pharmacist from Albert Ludwig University of Freiburg, Germany.
After teaching Chemisty and Toxicology for four years. He has worked for pharma-contract manufacturers for more than 30 years in a variety of positions, including production directorship for a wide range of dosage forms including solid oral forms, injectabilia, soft gelatin capsules and packaging. He took CEO positions since 1997 with the focus on restructuring companies that had were at the brink of bankrupcy.
Dr. Irene Rossi
Harro Höfliger, Germany
Dr. Irene Rossi holds Consultant for Inhalation Technology position at Harro Höfliger (Germany), supporting the team and the clients on product development and drug delivery matters, particularly focusing on nasal and inhalation delivery. She is also part of the INTO technical team together with experts from DFE Pharma and Sterling.
Irene obtained a MSc in 2014 and a PhD in Drugs, Biomolecules and Health Products at the University of Parma (Italy) in 2019.
In 2019 Dr. Rossi joined Nanopharm, An Aptar Pharma Company (UK) where she covers various roles. Recently, she was leading a group focused on the development and characterization of new formulation technologies for OINDP products comprising both small and large molecules.
Irene has many publications and filed 3 patent applications. She presented her work at more than 50 international conferences.
prof. gÜLAY DURMUŞ ALTUN
Girne American University, Cyprus
Professor Gülay Durmuş Altun is a distinguished professor in Nuclear Medicine and Physiology. Her research focuses on the application of nuclear medicine methodologies in pathophysiology and diagnosis of various diseases.
Prof. Durmuş-Altun is the founding chair of the Preclinical Study Group of the Turkish Society of Nuclear Medicine.
Prof. Durmuş-Altun is the founder of HELSE AID, a consultancy company. She is currently affiliated with the Girne American University, where she actively is involved in clinical research in nuclear medicine alongside preclinical molecular imaging, disease modelling, and the development of novel radiopharmaceuticals.
She graduated from Istanbul Medical Faculty in 1991, and obtained her doctorate in Nuclear Medicine in 1998. She obtained a second PhD in 2006 from Trakya University. She advised 12 PhD students and is (co)author of over 100 scientific publications, editor of 4 books and of more than 20 book chapters.
Prof. Lea Ann Dailey
University of Menna, Austria
Prof. Lea Ann Dailey is a pharmacist by training and completed her PhD at the Philipps University of Marburg, Germany, on biocompatibility testing of polymeric nanoparticles for the controlled release of drugs in the lung.
She worked in the private sector for many years as a formulation scientist for inhalation therapies at Nektar Therapeutics (now Novartis, San Carlos, CA, USA), followed by positions at the King’s College London, UK, the Martin Luther University Halle-Wittenberg, Germany, and the University of Vienna. Her research has focused on the design of dosage forms for the delivery of anti-infectives to the lung as well as the biocompatibility assessment of novel excipients for inhaled products.
Dr. Alfredo Garcia
AEMPS
The Spanish Agency of Medicines and Medical Devices
Alfredo García Arieta, Ph.D., is currently a Consultant for the WHO Prequalification of Medicines Programme.
He was previously Head of Area on Pharmacokinetics and Generic Medicines of the Division of Pharmacology and Clinical Evaluation in the Spanish Agency for Medicines and Health Care Products and member of the Methodology Working Party at the EMA as well as the drafting groups on the Guideline on Quality and Equivalence of Topical Products and the Guideline on Orally Inhaled Products.
He holds a Bachelor’s degree in Pharmacy (1993), a Master’s degree in Pharmaceutics and Industrial Pharmacy (1996) and a PhD in Pharmaceutical Technology (1999), all from Universidad Complutense, Madrid, Spain. Dr. García Arieta also holds a Master’s degree in Statistics in Health Sciences (2001) from the Universidad Autónoma de Barcelona.
Makino Junya
PMDAI Japanese Authority
Alfredo García Arieta, Ph.D., is currently a Consultant for the WHO Prequalification of Medicines Programme.
He was previously Head of Area on Pharmacokinetics and Generic Medicines of the Division of Pharmacology and Clinical Evaluation in the Spanish Agency for Medicines and Health Care Products and member of the Methodology Working Party at the EMA as well as the drafting groups on the Guideline on Quality and Equivalence of Topical Products and the Guideline on Orally Inhaled Products.
He holds a Bachelor’s degree in Pharmacy (1993), a Master’s degree in Pharmaceutics and Industrial Pharmacy (1996) and a PhD in Pharmaceutical Technology (1999), all from Universidad Complutense, Madrid, Spain. Dr. García Arieta also holds a Master’s degree in Statistics in Health Sciences (2001) from the Universidad Autónoma de Barcelona.
Dr. Başbuğ Öke
Eczacıbaşı, Türkiye
Dr. Başbuğ Öke is a pharmaceutical executive with a strong academic foundation and over 20 years of leadership experience in both national and international healthcare organizations. He received his undergraduate, master’s, and doctoral degrees from the Faculty of Pharmacy and the Department of Biochemistry at Istanbul University.
He began his professional career in business development and product management, later assuming senior leadership roles at Abdi İbrahim, Abbott, and AbbVie. From 2017 to 2021, he was based at AbbVie’s global headquarters in Chicago, serving as Director of Global Marketing and Commercial Operations in Neuroscience.
Since 2021, Dr. Öke has been serving as the General Manager of Eczacıbaşı Pharmaceutical Marketing, leading strategic transformation in a dynamic healthcare environment. He is also a member of the Audit Board of the Pharmaceutical Manufacturers Association of Turkey (IEIS) and chairs its Corporate Communications Working Group.
Combining deep scientific training with global industry experience, Dr. Öke continues to contribute to sectoral innovation and knowledge exchange between academia and the pharmaceutical sector.
.png)
DR. ARSUN ARTEL
Pulmocures, Türkiye
Dr. Arsun Artel is a technology executive with more than 20 years of experience in innovation and technology in the high-impact industries including defense systems and AI based software. He is presently the CTO of Pulmocures Drug Company, where he leads on operations and product innovation.
Previously, Dr. Artel served as the head of R&D at ISRA VISION Turkey, leading interdisciplinary teams in the development of state-of-the-art hardware and AI-based software. Throughout his career, he led multi-million-Euro military defense projects at TÜBİTAK MAM (The Scientific and Technological Research Council of Turkey Marmara Research Center). He was actively involved in plant design, CO₂ capture, manufacturing processes and salt recycling technologies. Dr. Artel has extensive knowledge in technical, and cross-functional collaboration, and has led many projects with operational efficiency, customer satisfaction, and innovative outputs.
Dr. Artel received his PhD in Chemical Engineering from the Illinois Institute of Technology, USA, his MS in Computer Engineering, and his BS in Chemical Engineering from Boğaziçi University.
Marco Franza
Amcor
Marco covered different roles in Sales, Business Development and Marketing for more than 40 years. As Inhalation devices have constantly been identified as a key growth factor for the company, Marco always had a particular focus on them, driven also by passionate personal interest.
Franza has managed Sales, Marketing and Key Accounts at Plastiape between 1997 to 2019. Since 2020 Franza is the Director Sales and Business Development at Global Inhalation & Medical Devices of Berry Global Healthcare.
Since May 2025, Franza serves in the same role under Amcor Healthcare, following the implementation of combination Amcor and Berry.
Franza had obtained his degree from the Università degli Studi di Milano
Dr. Ruth Cordoba - Rodriguez
AstraZeneca
Dr. Ruth is a Senior Director of Regulatory Affairs Chemistry, Manufacturing and Controls (CMC) in AstraZeneca in Gaithersburg, MD. She works in the biologics group and manages a team of regulatory strategy leads. Her previous jobs in US FDA as CMC reviewer and team leader and, Amgen as product quality leader focused on biologics and span 23 years of experience. During her career, Ruth has developed regulatory strategy and has reviewed biologic products at all stages of development and their life cycle. Ruth holds a PhD in biophysics from the University of Maryland where she did her post-doctoral research work.
MEHMET ÜZÜMCÜ
Gilbert Company
For more than 20 years, Dr. Üzümcü has been active in the field of Medical Device Development in various areas such as cardiology, oncology, nuclear medicine and endoscopy. In 2023 Mehmet has joined Gilbert as the Chief Scientific and Technology Officer, hence is in charge of the development of a next generation smart precision inhaler.
Dr. Mehmet Üzümcü has obtained his degree in Applied Physics from the Delft University of Technology and obtained his master's degree in the field of medical physics. Thereafter, he obtained a PhD in Medicine at Leiden University Medical Center, where he developed automated methods for analysis of cardiac function based on 4D MRI imaging.
Dr. Hanan Fael
Pulmocures
Dr. Hanan Fael earned her degree in Pharmacy from Aleppo University in 2002 and completed her PhD in 2015. Since then, she has accumulated nearly a decade of postdoctoral research experience at institutions including the University of Barcelona, Koç University, and Istanbul University. Her work focuses on enhancing the solubility of poorly soluble drugs through advanced formulation strategies. Since 2020, she has collaborated with the Pharmaceutical Technology team at Istanbul University and later joined Pulmocures—founded by Prof. Ayca Yıldız Peköz—where she contributes to the development of inhalable heparin and antiviral formulations, as well as in-situ gels for therapeutic applications.
Prof. Sadi Özkan
University of Akdeniz, Türkiye
Dr. Özdem graduated from Hacettepe University, Medical Faculty in 1989. After one year of experience in general surgery, he completed his specialty in medical pharmacology in Akdeniz University, Medical Faculty, Department of Medical Pharmacology. He is currently the head of the same department.
Dr. Özdem has focused on diabetes mellitus and hypertension in his experimental research and taken part as clinical investigator in more than twenty Phase 3 clinical trials with diabetic patients. He served as an instructor and consultant in clinical trials, and safety reporting in clinical trials, good clinical practice. He organized university-industry cooperations.
He is particularly interested in development and regulatory evaluation of biotechnological medicinal products, specifically of biosimilars, and has participated in educational activities and workshops on biological medical products and biosimilars organized by TİTCK. He is the editor and co-editor of two books on biosimilars.
Dr. Imco Sibum
Resyca, the Netherlands
Imco is Manager of Pharmaceutical Development at Rescya, located in Enschede, the Netherlands. He takes care of the pharmaceutical services, CMC, risk management, and clinical trial documentation. Imco has a pharmaceutical background and holds a Ph. D. from the University of Groningen, where he worked on dry powder inhalers at the group of Erik Frijlink, Paul Hagedoorn and Anne de Boer.
PROF. BEN FORBES
King's College London, UK
Ben is Professor of Pharmaceutics at King’s College London. He has a BPharm from King’s College London (1987) and a PhD in Drug Delivery from Strathclyde University (1996). He is a registered pharmacist in the UK and before doctoral studies, he worked in hospital pharmacy in London and Sydney, and for Inveresk Clinical Research in Edinburgh. He was appointed to the academic staff of King’s College London in 1997. Ben has worked extensively in the area of Nasal & Inhalation Drug Product Biopharmaceutics with interests in medicine formulation, the development and application of techniques to study respiratory drug transport and metabolism, and inhalation toxicology.
